Evelo Biosciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
October 21, 2021 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
October 13, 2021 07:00 ET
|
Evelo Biosciences, Inc.
–Data suggest SINTAX™ medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery– –EDP1867 reduced disease severity and incidence of relapse in murine model of multiple...
Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease
September 27, 2021 02:00 ET
|
Evelo Biosciences, Inc.
–Clinically and statistically significant improvement in PASI-50 score achieved––EDP1815 safety and tolerability data comparable to placebo in study––EDP1815 advancing towards registration studies in...
Evelo Biosciences to Present at 2021 Cantor Global Healthcare Conference
September 20, 2021 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
Evelo Biosciences Announces Issuance of U.S. Patent for Pharmaceutical Compositions of Single Strains of Naturally Occurring Bacteria as Medicines
September 09, 2021 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new type of orally delivered medicines, today...
Evelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors
September 07, 2021 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights
July 29, 2021 07:00 ET
|
Evelo Biosciences, Inc.
–EDP1815 Phase 2b data in psoriasis expected in 3Q 2021––Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated in 3Q 2021––Strengthened leadership team...
Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
July 22, 2021 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
Evelo Biosciences Announces Grant of Inducement Award
July 14, 2021 16:01 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced...
Evelo Biosciences Announces Grant of Inducement Award
June 16, 2021 16:01 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced...